Description
G0465
Approved for Medicare Advantage (NCD: 270.3)
ActiGraft is an Autologous blood-derived product for chronic, non-healing wounds (including diabetic wounds) that constructs a whole blood clot (WBC) gel containing whole cells: white cells, red cells, plasma, platelets, fibrin, stem cells, and fibrocyte precursors. Physicians in clinical settings use the gel to treat chronic, non-healing, open-cutaneous, soft tissue wounds. The procedure includes administration, dressings, phlebotomy, mixing, and other preparatory procedures per treatment.
An autologous, point-of-care wound management solution created from a patient’s whole blood, ActiGraft PRO serves as a protective covering and optimizes the body’s own healing potential once applied.
Key Points:
- Whole Blood
- No centrifuge required
- 5-minute coagulation
- 72% complete closure in 12 weeks
- Small, 100% recyclable packaging
Indications For Use
- Leg Ulcers
- Pressure Injury Wounds
- Diabetic Foot Ulcers
- Mechanically or Surgically Debrided Wounds
Contra-Indications
- Clinical Wound Infections
- Active Underlying Osteomyelitis
- Active Malignancy